<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837108</url>
  </required_header>
  <id_info>
    <org_study_id>NL43234.091.13</org_study_id>
    <nct_id>NCT01837108</nct_id>
  </id_info>
  <brief_title>Eplerenone and Extracellular Adenosine Formation</brief_title>
  <acronym>eplerenone01</acronym>
  <official_title>Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various studies have reported cardioprotective effects of mineralocorticoid receptor (MR)
      antagonists in the setting of an acute myocardial infarction. In a recent animal study, the
      protective effect of MR antagonists on infarct size was completely abolished in CD73
      knock-out and adenosine A2b receptor knock-out mice, and by co-administration of adenosine
      receptor antagonists in rats. These findings suggest that extracellular formation of
      adenosine is crucial for this protective effect and that MR antagonists stimulate
      extracellular adenosine formation by the enzyme CD73.

      To investigate whether eplerenone promotes adenosine receptor stimulation by activating CD73,
      the investigators will measure forearm blood flow in response to various dosages of
      dipyridamole with the use of plethysmography. Dipyridamole increases the extracellular
      endogenous adenosine concentration by inhibition of the ENT transporter and induces local
      vasodilation. Therefore, the vasodilator effect of dipyridamole accurately reflects
      extracellular adenosine formation by the CD73 enzyme.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forearm blood flow response</measure>
    <time_frame>8 days</time_frame>
    <description>Forearm blood flow response to the intrabrachial administration of incremental dosages of dipyridamole, after treatment with eplerenone, compared to placebo. The forearm blood flow will be measured by plethysmography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>forearm blood flow</measure>
    <time_frame>8 days</time_frame>
    <description>Forearm blood flow response to the intrabrachial administration of incremental dosages of dipyridamole, with and without caffeine, after eplerenone treatment. The forearm blood flow will be measured by plethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forearm blood flow</measure>
    <time_frame>8 days</time_frame>
    <description>Forearm blood flow to incremental periods of arterial occlusion. The forearm blood flow will be measured by plethysmography.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>24 hours urine sample</measure>
    <time_frame>1 day</time_frame>
    <description>Twenty-four hours urine samples will be collected and sodium and creatinine will be determined, to ensure that salt intake is approximately the same during both treatment days.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>fully mimicking placebo 50 mg bid during 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eplerenone 50 mg bid during 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen</description>
    <arm_group_label>eplerenone</arm_group_label>
    <other_name>Inspra, RVG 29963</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex

          -  Age 18-40 years

          -  Healthy

          -  Written informed consent

        Exclusion Criteria:

          -  Smoking

          -  Hypertension (Blood pressure &gt;140 mmHg and/or &gt;90 mmHg - SBP/DBP-)

          -  Hypotension (Blood pressure &lt;100 mmHg and/or &lt;60 mmHg -SBP/DBP-)

          -  Diabetes Mellitus (fasting glucose &gt; 6.9 mmol/L or random &gt; 11.0 mmol/L in venous
             plasma)

          -  History of any cardiovascular disease

          -  Angina pectoris

          -  History of chronic obstructive pulmonary disease (COPD) or asthma

          -  Alcohol and/or drug abuse

          -  Concomitant use of medication

          -  Renal dysfunction (MDRD &lt; 60 ml/min/1.73 m2)

          -  Liver enzyme abnormalities (ALAT &gt; twice upper limit of normality)

          -  Serum potassium â‰¥ 4.8 mmol/L

          -  Fasting total cholesterol &gt; 6.0 mmol/L

          -  Second/third degree AV-block on electrocardiography
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Riksen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Rongen, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

